1,796 material Form 8-K filings that 1,448 companies we cover made with the SEC in May 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
ANI Pharmaceuticals reported first quarter 2026 revenue of $237.5 million, up 20.5% from a year earlier, and GAAP net income of $29.5 million, or $1.28 per diluted share, compared with $0.69 a year earlier. The company raised its 2026 total net revenue, adjusted EBITDA and adjusted diluted EPS guidance and authorized a $100 million share repurchase program.
Q1 2026 total net revenues of $237.5 million, up 20.5%; Cortrophin Gel net revenues of $75.1 million, up 42.1%
GAAP diluted EPS of $1.28 vs. $0.69 a year earlier; adjusted non-GAAP diluted EPS of $2.05 vs. $1.70
2026 total net revenue guidance raised to $1,080 million to $1,140 million from $1,055 million to $1,115 million; adjusted non-GAAP EBITDA raised to $285 million to $300 million
Board authorized a $100 million share repurchase program effective May 8, 2026, running through May 2029; Brands net revenues fell 50.9%
Interface reported first-quarter 2026 net sales of $331 million, up 11.3% year over year, with GAAP diluted EPS of $0.40 versus $0.22 a year earlier. The company raised its full-year 2026 net sales outlook to $1.450 billion to $1.480 billion from $1.420 billion to $1.460 billion, which signals higher expected revenue for shareholders this year.
Q1 2026 net sales $331.0 million, up 11.3%; up 6.8% on a currency-neutral basis
GAAP diluted EPS $0.40 vs. $0.22; adjusted diluted EPS $0.41 vs. $0.25, up 64.0%
Full-year 2026 net sales guidance raised to $1.450 billion to $1.480 billion; capital expenditure guidance raised to $60 million from $55 million
Company repurchased $12.0 million of common stock in the first quarter
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.